PeproMene Bio
PrivateLast Round
Corporate Funding
Dec 19, 2024
Total Funding Raised
$55.2M
Company Overview
PeproMene Bio is a clinical-stage biotechnology company that develops novel CAR T-cell therapies to treat cancers and immune disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
PeproMene Bio Comparables
Compare PeproMene Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Mustang Bio Inc | 75% | |
| Gilead Sciences | 73% | |
| Novartis | 72% | |
PeproMene Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Corporate Funding | Dec 19, 2024 | ||||
| Series B | Jun 11, 2018 | ||||
| Series A | Sep 1, 2017 |
Key People
Founding team and executive leadership
PeproMene Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| KB Investment | Series B |
| KB Investment | Series B |
| Seven Tree Equity Partners | Series B |
| Institute for Follicular Lymphoma Innovation | Corporate Funding |
| Solidus Investment | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 25, 2025
Presented BAFF-R CAR-T therapy trial results at ASH 2025.
- Nov 25, 2025
Showcased breakthrough results for BAFF-R CAR-T therapy at ASH 2025.
PeproMene Bio Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about PeproMene Bio's valuation, stock price, and market status.